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Patients on conventional hemodialysis have low levels of
25-hydroxy-vitamin D probably due to diet and decreased
cutaneous synthesis. As 1,25 dihydroxy-vitamin D synthesis is
substrate-dependent in end-stage renal disease, this could be
a contributing factor to low 1,25 dihydroxy-vitamin D levels
in patients undergoing conventional hemodialysis.
We converted 35 patients historically on conventional
hemodialysis to nocturnal hemodialysis for a minimum
of 6 months thereby significantly increasing sessional
equilibrated Kt/V from an average of 1.30 to an average
of 2.01. Dietary restrictions were also removed. Serum
phosphorus significantly fell, whereas the serum calcium,
parathyroid hormone, and the mean dose of calcitriol did not
change after the conversion. Significant increases in both
25-hydroxy and 1,25-dihydroxy-vitamin D levels were seen
after hemodialysis mode conversion. A significant correlation
was found between the dialysis dose and the levels of both
hydroxylated forms of vitamin D. We suggest that improving
uremia by nocturnal hemodialysis in the absence of
exogenous supplementation is associated with increased
25 and 1,25-hydroxy-vitamin D levels. Additionally,
normalization of serum phosphorus may improve
1a-hydroxylation thereby enhancing substrate-dependent
generation of 1,25-dihydroxy-vitamin D in chronic dialysis
patients.
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Patients with advanced chronic kidney disease and end-stage
renal disease (ESRD) are known to have low levels of 1,25
dihydroxy-vitamin D (1,25D) due to loss of renal 1a-hydroxy-
lation, but less attention has been paid to 25-hydroxy-vitamin D
(25D) insufficiency (15–30 ng/ml) and deficiency (o15 ng/ml)
in this population. There are now several studies demonstrating
a high prevalence of 25D insufficiency among patients with
chronic kidney disease and ESRD.1–5
Although 1,25D is considered to be the ‘active’ form of
vitamin D, there is an emerging literature suggesting that 25D
exerts important and independent effects on parathyroid
hormone (PTH), renal bone disease,4,6,7 and muscle func-
tion.8–11 These independent effects may be due to 25D itself
or alternatively may be the result of local tissue activation of
25D to 1,25D. Local tissue activation of 25D to 1,25D has
been demonstrated in a variety of cell types,12 including the
parathyroid glands, in which intracrine activation of 25D to
calcitriol could effectively suppress PTH synthesis.13 More-
over, peripheral blood monocytes in conventional hemodialysis
(CHD) patients have been well characterized to convert 25D to
1,25D,14 implicating the direct clinical importance of 25D
insufficiency in kidney failure. The etiology of the 25D
insufficiency observed in patients with ESRD appears to be
multifactorial. The contributors may include dietary restriction
on foods high in phosphorus (some of which are also rich in
vitamin D), decreased sun exposure, and impaired cutaneous
generation of vitamin D in the presence of uremia.15
Patients on nocturnal home hemodialysis (NHD) (5–6
sessions/week; 6–8 h/session) have normal plasma phosphate
levels without the need for dietary restrictions.16,17 In
addition, NHD patients may have enhanced cutaneous
generation of vitamin D due to an improvement of the
uremic milieu. We, therefore, conducted an observational
cohort study to assess whether conversion from CHD to
NHD would be associated with a significant increase in 25D
in the absence of exogenous supplementation. In addition,
given that 1,25D generation may be substrate-dependent in
ESRD, we sought to determine whether an increase in 25D
may lead to an augmentation of 1,25D levels.
RESULTS
The study population consisted of 35 hemodialysis patients
(aged 45711 years, 66% male). Their baseline demographic
characteristics are summarized in Table 1. Levels of 25D were
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o30 ng/ml in 22/35 (63%) of patients, with levelso15 ng/ml
in 6/35 (17%). Levels of 1,25D were low (o16 pg/ml) in 25/
35 (71%) of the patients.
Patients were on NHD for a mean of 27714 months at
the time of the follow-up measurement. In addition to
doubling dialysis frequency, NHD delivered a significantly
higher dose per session than CHD (1.3070.3 versus
2.0170.4, Po0.001). The laboratory values of 25D, 1,25D,
calcium, phosphorus, and PTH, as well as the mean calcitriol
dose before and after conversion to NHD are shown in
Table 2. Levels of 25D increased significantly from 26.0
(10.8–41.2) (median (quartiles)) to 32.0 (6.4–57.6) ng/ml,
P¼ 0.009. Levels of 1,25D increased significantly from 7.32
(0.9–19.6) to 11.94 (0.02–23.9) pg/ml, P¼ 0.004 (Figure 1).
Sun exposure did not differ at the time of baseline testing and
subsequent testing (153762 h (baseline) versus 152736 h
(after conversion to nocturnal hemodialysis), P¼ 0.9). Of
our patient cohort, eight patients had an increase in their
calcitriol dose, 12 had a decrease in their dose, and 15
patients were not on vitamin D supplementation at any time.
Consistent increases in 25D (from 23.4 (9–37.8) to 34.1
(4.9–63.3) ng/ml, P¼ 0.03) and 1,25D (from 2.69 (0.9–8.9)
(CHD) to 10.78 (1.2–20.4) (NHD) pg/ml, P¼ 0.005) were
demonstrated among patients who did not receive any
vitamin D supplementation at any time. 25D and 1,25D
tended to increase in the subgroup of patients who had an
increase in calcitriol dose. In contrast, there was no change in
vitamin D status in those patients who had a decrease in
calcitriol dose after conversion to nocturnal hemodialysis
(Table 2).
Five of six patients not receiving any calcitriol supple-
mentation who were also anephric at baseline had an increase
in 1,25D levels after conversion to NHD (from 2.31 (1.2–8.6)
to 10.97 (3.6–18.4), P¼ 0.04). Serum calcium and PTH
levels did not change significantly on conversion to NHD,
phosphate decreased from 1.4170.44 mmol/l on CHD to
0.8470.28 mmol/l on NHD (P¼ 0.02).
Table 1 | Patient demographics
Mean age (years) 45711
Gender (male/female) (%) 66/34
Race (%)
Caucasian/Asian 97
Black 3
Renal disease (%)
Glomerulonephritis 54
Polycystic kidney disease 14
Diabetes mellitus 6
Other 26
Anuria at baseline (%) 49
Mean time on NHD at time of follow-up measurement (months) 27714
NHD, nocturnal hemodialysis.
Table 2 | Effects of NHD on vitamin D levels
CHD NHD P-value
25D level (ng/ml)
All patients (n=35) 26.0 [10.8–41.2] 32.0 [6.4–57.6] 0.009
Patients with an increase in calcitriol (n=8) 25.7 [4.8–46.4] 30.6 [12.8–69.1] 0.1
Patients with a decrease in calcitriol (n=12) 30.2 [7.6–52.8] 33.6 [19.2–48] 0.5
Patients not on calcitriol (n=15) 23.4 [9.0–37.8] 34.1 [4.9–63.3] 0.03
1,25D level (pg/ml)
All patients (n=35) 7.32 [0.9–19.6] 11.94 [0.02–23.9] 0.004
Patients with an increase in calcitriol (n=8) 6.16 [1.5–19.8] 18.7 [8.9–28.4] 0.2
Patients with a decrease in calcitriol (n=12) 11.7 [1.2–31.0] 8.2 [0.6–15.8] 0.8
Patients not on calcitriol (n=15) 2.69 [0.9–8.9] 10.78 [1.2–20.4] 0.005
PTH (pmol/l) 30.5747.5 24.3734.1 0.50
Calcium (mmol/l) 2.4770.19 2.4970.20 0.72
Phophate (mmol/l) 1.3970.44 1.0670.48 0.006
Calcitriol dose (mg/week) 0.7671.10 0.5470.85 0.27
CHD, conventional hemodialysis; NHD, nocturnal hemodialysis; PTH, parathyroid hormone; s.d., standard deviation.
Demographic and laboratory data are reported as mean7s.d. or median and quartiles for those variables found to have a skewed distribution.
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Figure 1 | Vitamin D levels before and after conversion to NHD in
all patients (n¼ 35). *Po0.05 compared with CHD. Abbreviations:
CHD 25D, 25-hydroxy-vitamin D while on conventional hemodialysis;
CHD 1,25D, 1,25 dihydroxy-vitamin D while on nocturnal
hemodialysis; NHD 25 D, 25-hydroxy-vitamin D while on nocturnal
hemodialysis; NHD 1,25 D, 1,25 dihydroxy-vitamin D while on
nocturnal hemodialysis.
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The change in 25D levels correlated with the change in
1,25D levels after conversion to NHD (r¼ 0.45, P¼ 0.007).
No correlation between the change in phosphate levels and
the change in 1,25D levels was seen. Dialysis dose correlated
with 25D levels (r¼ 0.27, P¼ 0.03) and 1,25D levels
(r¼ 0.28, P¼ 0.02).
DISCUSSION
This is the first study to evaluate the effect of conversion from
CHD to NHD on vitamin D levels. Our findings confirm the
high prevalence of 25D insufficiency in the ESRD population,
and demonstrate a significant increase in both 25D and
1,25D after conversion to NHD. A mathematical correlation
between vitamin D levels and dialysis dose was seen. In
addition, changes in 25D and 1,25D were directly related to
each other. Taken together, our results suggest a mechanistic
link between the augmentation of uremic clearance by NHD
and its metabolic effects on vitamin D synthesis.
From a simplistic viewpoint, a rise in 25D levels after
conversion to NHD may be related to an increase in oral
intake, an augmented cutaneous generation or a reduction in
degradation of 25D. In patients on NHD, the removal of
dietary restrictions on foods high in phosphate (some of
which are also rich in vitamin D) may directly augment 25D
levels. However, experimental evidence also suggests that
uremic toxins may interfere with cutaneous synthesis of
vitamin D.15 These putative toxins behave in a manner that is
analogous to melanin accumulated at the lower malpighian
cellular layers, where cutaneous synthesis of vitamin D
occurs.18,19 Finally, a decrease in calcitriol dose requirement
could also reduce 1,25D induction of 24-hydroxylase, the
enzyme responsible for 1,25D and 25D degradation thereby
increasing the half-life of both metabolites.20 It is interesting
to note that among the subgroup of patients who had a
decrease in calcitriol dose requirement, there was no change
in vitamin D status. At the present, our data do not support
the hypothesis that reduction in metabolic breakdown is the
principal cause of our observation; rather it is tempting to
propose that an increase in oral intake or an enhanced
cutaneous generation of vitamin D may be directly
responsible for the observed increase in 25D.
There is now an emerging body of evidence to suggest the
importance of 25D in patients with chronic kidney disease
and ESRD. Eastwood et al.6 examined 22 chronic kidney
disease patients and found that osteomalacia only occurred in
those who were 25D-deficient. Similarly, a cross-sectional
study of 113 CHD patients demonstrated that plasma 25D
levels were inversely correlated with PTH, and that radio-
graphic evidence of osteomalacia was not seen in patients with
plasma 25D 416 ng/ml.7 In addition to the potential effects on
PTH and renal bone disease, experimental data also support
the anabolic effects of 25D on muscle function.8,9,20 Clearly, the
clinical significance of a higher 25D level observed in our
cohort of ESRD patients requires further study.
In addition to the increase in 25D, we also documented a
rise in 1,25D after conversion to NHD in our cohort. The low
basal levels of 1,25D in a patient population in whom renal
1a-hydroxylase activity is diminished should not be surpris-
ing. However, it is intriguing to note that 1,25D levels may be
increased without exogenous supplementation by conversion
to NHD. Under normal circumstances, 1,25D production is
regulated by renal 1a-hydroxylase activity, and is independent
of its substrate, 25D.18 It is plausible that NHD may increase
1a-hydroxylase activity by normalizing plasma phosphate
leading to an elevation in 1,25D. However, the absence
of a correlation between the change in phosphate and
the change in 1,25D would argue against this being the
primary mechanism accounting for the rise in 1,25D.
Given the direct association between the changes in 25D
and 1,25D levels, our data are consistent with the notion that
1,25D generation is largely substrate-dependent in ESRD
patients.
It is important to note that disturbances of vitamin D
sterol metabolism and low levels of 1,25D have been
implicated in the development of atherosclerotic diseases.21
A deficiency in 1,25D has also been linked with the
development of hypertension22,23 and increases in the
cardiovascular mortality in patients with renal failure.24
Treatment with active vitamin D has been shown to cause
regression of left ventricular hypertrophy.25–27 Recently,
increasing the dose and frequency of dialysis by NHD has
been demonstrated, in both short-and long-term studies, to
reverse several important risk factors for adverse cardiovas-
cular events in ESRD patients, such as hypertension, left
ventricular hypertrophy, systolic dysfunction, conduit artery
stiffness, and endothelium-dependent vasodilation.28–30 It is
tempting to speculate that the present documentation of
simultaneous increases in both 25D and 1,25D levels may
contribute to the cardiovascular advantages of NHD,
although this requires further investigation.
Our study is limited by its observational nature and the
relative small sample size. Although we did not find a
difference in sun exposure before and after conversion to
NHD, we were unable to determine the precise amount of
sun exposure on an individual basis. It is also unclear
whether the significant increases in 25D and 1,25D are
associated with clinical benefits. Further studies are required
to determine whether the observed rise in 1,25D is due to
increased renal (or extrarenal) 1a-hydroxylase activity, or
increased uptake of 25D by renal cells or extrarenal sources.
Given that this is a clinical study, it was not possible to assess
the influence of calcitriol on the endocytic uptake of vitamin
D in the remnant kidney.31 Moreover, 25D uptake by
monocytes in ESRD patients was not studied because limited
information may be derived reflecting the diverse nonrenal
sources of calcitriol.32 In addition, dissection of the
metabolites of 25D in circulation may also enhance our
understanding of the mechanisms by which NHD augments
25D and 1,25D levels. Future experiments will hopefully add
to the understanding of the relative contribution of enhanced
cutaneous generation of vitamin D, renal (or extrarenal) 25D
uptake, and activation to 1,25D to the local and systemic
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actions of the vitamin D endocrine system under different
degrees of uremia.
In summary, conversion from CHD to NHD resulted in
an increase in 25D levels as well as an increase in 1,25D levels
in the absence of exogenous supplementation. Our data also
support the substrate dependence of 1,25D generation in
ESRD patients. Further exploration of the basis for the rise in
vitamin D levels and its clinical significance in the NHD
population is warranted.
MATERIALS AND METHODS
Thirty-five consecutive ESRD patients at the Toronto General
Hospital, University Health Network, who were converted from
CHD to NHD were included in this prospective longitudinal cohort
study. Research Ethics Board approval was obtained from the
Toronto General Hospital.
Dialysis prescriptions
CHD was performed using F80 polysulfone dialysers (Fresenius
Medical Care, Lexington, MA, USA). The dialysate composition
was as follows: Naþ 140 mM, Kþ 1–3 mM, Ca2þ 1.25–1.5 mM, and
HCO3
 35–40 mM. The blood flow rate was 400 ml/min, and the
dialysate flow rate was 500–750 ml/min. CHD was defined as 4-h
sessions three times per week.
NHD was performed using either F80 or Polyflux dialysers
(Gambro Inc., Lund, Sweden). The dialysate composition did not
differ between CHD and NHD, except for the addition of phosphate
supplementation in most NHD patients to maintain normal plasma
phosphate levels. The blood flow rate was 200–300 ml/min, and the
dialysate flow rate was 350 ml/min. NHD was defined as 6–8 h
sessions 5–6 times per week.
Study protocol and biochemical analysis
Consecutive NHD patients who had baseline measurements of
vitamin D levels before conversion from CHD and who had been on
NHD for at least 6 months were included. Patients’ age, sex,
ethnicity, etiology of ESRD, and vitamin D therapy were noted. No
patients were receiving inactive forms of vitamin D. The presence or
absence of residual renal function (defined as 4100 cc/day) at
baseline before conversion to NHD was noted.
Levels of 25D and 1,25D, as well as calcium, phosphate, and PTH
were measured while on CHD and again at least 6 months after
conversion to NHD. All blood samples were drawn before the
administration of calcitriol. Calcitriol dose was also noted at the
time of both blood test measurements. Specimens for vitamin D
analysis were processed by the Toronto Medical Laboratory,
University Health Network. Levels of 25D and 1,25D were measured
using the DiaSorin radioimmunoassay kit. Intact PTH was
measured using the Immulite 2000 assay. Dialysis dose per treatment
was estimated by equilibrated Kt/V (eKt/V) as described by
Daugirdas et al.33 where eKt/V¼ spKt/V0.6(spKt/V)/tþ 0.03
(spKt/V¼ single pool Kt/V, K is the delivered clearance, t the
dialysis time, and V the urea distribution volume). Single pool Kt/V
was determined using blood urea reduction ratio.34 Estimated sun
exposure during the month of blood sampling was obtained from
Environment Canada.
The primary end point was a within-subject difference in 25D
levels before and after conversion to NHD. Secondary outcomes
were within-subject differences in levels of 1,25D, Kt/V, PTH,
calcium, phosphate, and calcitriol use. Correlations were sought
between changes in 25D, changes in 1,25D and changes in
phosphate.
Statistical analysis
Demographic and laboratory data are reported as mean7s.d. or
median and quartiles for those variables found to have a skewed
distribution. The effect of modality switch on 25D and 1,25D levels
was studied using the Wilcoxon-rank sum test with an a level of
0.05. A mathematical correlation between vitamin D levels and
biochemical indices was tested using Pearson’s correlation coefficient.
To limit confounding by concurrent oral or intravenous
administration of activated vitamin D, or because of residual renal
function we identified two subgroups of patients who were (i) not
receiving active vitamin D and (ii) anuric and not taking active
vitamin D. Comparisons were made using Wilcoxon-rank test with
an a of 0.05.
All statistical analyses were performed using the SPSS statistical
package (SPSS-10, Chicago, IL, USA).
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